Related Experiment Video

Updated: Jan 25, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.3K

Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer

Yuanyuan Pei1, Liang Chen1, Yukun Huang1

  • 1Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Lane 826, Zhangheng Road, Shanghai, 201203, P. R. China.

Small (Weinheim an Der Bergstrasse, Germany)
|April 30, 2019
PubMed

Insights

This study introduces a novel sequential therapy for pancreatic cancer, targeting both TGF-β and KRAS pathways. This dual-action approach effectively overcomes treatment resistance and improves survival rates in preclinical models.

Area of Science:

  • Oncology
  • Nanomedicine
  • Biotechnology

Background:

  • Pancreatic cancer exhibits high aggressiveness and resistance to current treatments, largely due to a suppressive tumor microenvironment (TME) and common KRAS mutations.
  • The transforming growth factor beta (TGF-β) pathway drives TME formation, while KRAS mutations contribute to poor patient outcomes, necessitating combination therapies.

Purpose of the Study:

  • To develop and evaluate a novel sequential-targeting strategy for pancreatic cancer therapy by simultaneously targeting TGF-β and KRAS pathways.
  • To overcome the limitations of the TME and address undruggable targets in pancreatic cancer cells.

Main Methods:

  • Construction of antifibrotic fraxinellone-loaded CGKRK-modified nanoparticles (Frax-NP-CGKRK) to target TGF-β signaling.
  • Application of siRNA-loaded lipid-coated calcium phosphate (LCP) biomimetic nanoparticles (siKras-LCP-ApoE3) for KRAS interference.
  • Sequential administration of nanoparticles to target tumor stroma and then tumor cells.

Main Results:

  • Frax-NP-CGKRK nanoparticles effectively targeted tumor sites, reversed cancer-associated fibroblasts, reduced stromal density, and improved tumor perfusion.
  • siKras-LCP-ApoE3 nanoparticles were efficiently internalized, leading to specific silencing of KRAS mutations.
  • The sequential-targeting strategy significantly improved survival rates in pancreatic tumor-bearing animals compared to gemcitabine treatment.

Conclusions:

  • Simultaneous targeting of TGF-β and KRAS pathways via a sequential nanoparticle delivery system offers a promising therapeutic strategy for pancreatic cancer.
  • This approach effectively remodels the TME and inhibits oncogenic KRAS, leading to enhanced anti-tumor efficacy and prolonged survival.
Keywords:
KRASTGF-βpancreatic cancersequential therapy

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K
Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

11.1K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
Mutations01:39

Mutations

Overview
94.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K